Ind Swift Share Price
Sector: Major Drugs
18.13 -0.50 (-2.68%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
17.99
Today’s High
19.45
52 Week Low
12.00
52 Week High
34.49
18.22 -0.39 (-2.10%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
18.10
Today’s High
19.25
52 Week Low
12.00
52 Week High
34.70
Key Metrics
- Market Cap (In Cr) 98.2
- Beta 0.27
- Div. Yield (%) 0
- P/B -
- TTM P/E 0.24
- Sector P/E 22.43
- Open Price 18.44
- Prev Close 18.63
Ind Swift Analysis
Price Analysis
-
1 Week16.87%
-
3 Months45.41%
-
6 Month-36.36%
-
YTD-44.87%
-
1 Year-15.45%
Risk Meter
- 55% Low risk
- 55% Moderate risk
- 55% Balanced Risk
- 55% High risk
- 55% Extreme risk
Ind Swift News
Nepal govt thanks India for ‘swift’ efforts to evacuate nationals from Iran
2 min read . 21 Jun 2025NRIs snap up Privana North condominiums as DLF clocks ₹11,000 crore in bookings
2 min read . 18 Jun 2025Ind Swift Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 515.23
- Selling/ General/ Admin Expenses Total
- 91.81
- Depreciation/ Amortization
- 23.5
- Other Operating Expenses Total
- 140.26
- Total Operating Expense
- 235.79
- Operating Income
- 279.45
- Net Income Before Taxes
- 287.91
- Net Income
- 283.45
- Diluted Normalized EPS
- 1.44
- Period
- 2025
- Total Assets
- 727.95
- Total Liabilities
- 1130.28
- Total Equity
- -402.33
- Tangible Book Valueper Share Common Eq
- -76.25
- Period
- 2025
- Cashfrom Operating Activities
- 15.86
- Cashfrom Investing Activities
- 3.23
- Cashfrom Financing Activities
- -12.71
- Net Changein Cash
- 6.37
- Period
- 2024
- Total Revenue
- 502.25
- Selling/ General/ Admin Expenses Total
- 78.32
- Depreciation/ Amortization
- 27.11
- Other Operating Expenses Total
- 88.79
- Total Operating Expense
- 475.39
- Operating Income
- 26.86
- Net Income Before Taxes
- 16.46
- Net Income
- 14.23
- Diluted Normalized EPS
- 3.44
- Period
- 2024
- Total Assets
- 654.47
- Total Liabilities
- 1345.3
- Total Equity
- -690.83
- Tangible Book Valueper Share Common Eq
- -129.48
- Period
- 2024
- Cashfrom Operating Activities
- 15.28
- Cashfrom Investing Activities
- 76.61
- Cashfrom Financing Activities
- -42.08
- Net Changein Cash
- 49.81
- Period
- 2023
- Total Revenue
- 410.96
- Selling/ General/ Admin Expenses Total
- 69.15
- Depreciation/ Amortization
- 28.67
- Other Operating Expenses Total
- 81.71
- Total Operating Expense
- 336.99
- Operating Income
- 73.97
- Net Income Before Taxes
- 26.04
- Net Income
- 26.04
- Diluted Normalized EPS
- -6.42
- Period
- 2023
- Total Assets
- 649.21
- Total Liabilities
- 1353.91
- Total Equity
- -704.7
- Tangible Book Valueper Share Common Eq
- -132.3
- Period
- 2023
- Cashfrom Operating Activities
- 73.05
- Cashfrom Investing Activities
- -29.35
- Cashfrom Financing Activities
- -46.56
- Net Changein Cash
- -2.85
- Period
- 2022
- Total Revenue
- 397.71
- Selling/ General/ Admin Expenses Total
- 63.15
- Depreciation/ Amortization
- 32.07
- Other Operating Expenses Total
- 78.18
- Total Operating Expense
- 383.7
- Operating Income
- 14.02
- Net Income Before Taxes
- -19.6
- Net Income
- -20.02
- Diluted Normalized EPS
- -3.79
- Period
- 2022
- Total Assets
- 631.76
- Total Liabilities
- 1352.08
- Total Equity
- -720.32
- Tangible Book Valueper Share Common Eq
- -134.91
- Period
- 2022
- Cashfrom Operating Activities
- 50.2
- Cashfrom Investing Activities
- -18.42
- Cashfrom Financing Activities
- -44.6
- Net Changein Cash
- -12.81
- Period
- 2021
- Total Revenue
- 356.06
- Selling/ General/ Admin Expenses Total
- 55.79
- Depreciation/ Amortization
- 32.7
- Other Operating Expenses Total
- 72.35
- Total Operating Expense
- 348.58
- Operating Income
- 7.48
- Net Income Before Taxes
- -29.49
- Net Income
- -29.82
- Diluted Normalized EPS
- -5.36
- Period
- 2021
- Total Assets
- 671.57
- Total Liabilities
- 1366.74
- Total Equity
- -695.16
- Tangible Book Valueper Share Common Eq
- -130.55
- Period
- 2021
- Cashfrom Operating Activities
- 83.19
- Cashfrom Investing Activities
- -16.71
- Cashfrom Financing Activities
- -54.25
- Net Changein Cash
- 12.23
- Period
- 2020
- Total Revenue
- 329.52
- Selling/ General/ Admin Expenses Total
- 52.53
- Depreciation/ Amortization
- 33.59
- Other Operating Expenses Total
- 66.68
- Total Operating Expense
- 333.29
- Operating Income
- -3.77
- Net Income Before Taxes
- -16.66
- Net Income
- -19.12
- Diluted Normalized EPS
- -4.3
- Period
- 2020
- Total Assets
- 601.65
- Total Liabilities
- 1314.76
- Total Equity
- -713.12
- Tangible Book Valueper Share Common Eq
- -134.62
- Period
- 2020
- Cashfrom Operating Activities
- 34.6
- Cashfrom Investing Activities
- -11.35
- Cashfrom Financing Activities
- -26.2
- Net Changein Cash
- -2.96
- Period
- 2019
- Total Revenue
- 289.03
- Selling/ General/ Admin Expenses Total
- 49.93
- Depreciation/ Amortization
- 33.97
- Other Operating Expenses Total
- 67.26
- Total Operating Expense
- 285.49
- Operating Income
- 3.54
- Net Income Before Taxes
- 8.19
- Net Income
- 8.19
- Diluted Normalized EPS
- -3.21
- Period
- 2019
- Total Assets
- 598.42
- Total Liabilities
- 1275.16
- Total Equity
- -676.74
- Tangible Book Valueper Share Common Eq
- -128.65
- Period
- 2019
- Cashfrom Operating Activities
- 42.79
- Cashfrom Investing Activities
- -13.71
- Cashfrom Financing Activities
- -13.03
- Net Changein Cash
- 16.05
- Period
- 2025-03-31
- Total Revenue
- 144.9
- Selling/ General/ Admin Expenses Total
- 24.2
- Depreciation/ Amortization
- 7.17
- Other Operating Expenses Total
- 52.46
- Total Operating Expense
- -117.68
- Operating Income
- 262.58
- Net Income Before Taxes
- 261.05
- Net Income
- 256.6
- Diluted Normalized EPS
- 14.65
- Period
- 2025-03-31
- Total Assets
- 727.95
- Total Liabilities
- 1130.28
- Total Equity
- -402.33
- Tangible Book Valueper Share Common Eq
- -76.25
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 15.86
- Cashfrom Investing Activities
- 3.23
- Cashfrom Financing Activities
- -12.71
- Net Changein Cash
- 6.37
- Period
- 2024-12-31
- Total Revenue
- 120.13
- Selling/ General/ Admin Expenses Total
- 21.15
- Depreciation/ Amortization
- 5.57
- Other Operating Expenses Total
- 36.2
- Total Operating Expense
- 118.37
- Operating Income
- 1.77
- Net Income Before Taxes
- -5.5
- Net Income
- -5.5
- Diluted Normalized EPS
- -1.02
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 136.35
- Selling/ General/ Admin Expenses Total
- 21.12
- Depreciation/ Amortization
- 5.39
- Other Operating Expenses Total
- 30.94
- Total Operating Expense
- 127.33
- Operating Income
- 9.01
- Net Income Before Taxes
- 4.11
- Net Income
- 4.11
- Diluted Normalized EPS
- 0.76
- Period
- 2024-09-30
- Total Assets
- 685.57
- Total Liabilities
- 1344.04
- Total Equity
- -658.47
- Tangible Book Valueper Share Common Eq
- -123.49
- Period
- 2024-09-30
- Cashfrom Operating Activities
- -16.24
- Cashfrom Investing Activities
- 31.76
- Cashfrom Financing Activities
- -9.81
- Net Changein Cash
- 5.71
- Period
- 2024-06-30
- Total Revenue
- 113.85
- Selling/ General/ Admin Expenses Total
- 19.93
- Depreciation/ Amortization
- 5.37
- Other Operating Expenses Total
- 26.99
- Total Operating Expense
- 116
- Operating Income
- -2.15
- Net Income Before Taxes
- 28.24
- Net Income
- 28.24
- Diluted Normalized EPS
- 5.21
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 135.23
- Selling/ General/ Admin Expenses Total
- 20.9
- Depreciation/ Amortization
- 6.88
- Other Operating Expenses Total
- 28.3
- Total Operating Expense
- 127.62
- Operating Income
- 7.61
- Net Income Before Taxes
- 39.77
- Net Income
- 37.54
- Diluted Normalized EPS
- 6.95
- Period
- 2024-03-31
- Total Assets
- 654.47
- Total Liabilities
- 1345.3
- Total Equity
- -690.83
- Tangible Book Valueper Share Common Eq
- -129.48
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 15.28
- Cashfrom Investing Activities
- 76.61
- Cashfrom Financing Activities
- -42.08
- Net Changein Cash
- 49.81
- Period
- 2023-12-31
- Total Revenue
- 102.56
- Selling/ General/ Admin Expenses Total
- 20.46
- Depreciation/ Amortization
- 6.78
- Other Operating Expenses Total
- 21.32
- Total Operating Expense
- 104.85
- Operating Income
- -2.29
- Net Income Before Taxes
- -14.97
- Net Income
- -14.97
- Diluted Normalized EPS
- -2.76
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Ind Swift Technical
Moving Average
SMA
- 5 Day15.91
- 10 Day16.54
- 20 Day16.72
- 50 Day14.91
- 100 Day14.84
- 300 Day19.52
Ind Swift Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Welcure Drugs And Pharmaceutic
- 12.96
- -0.68
- -4.99
- 15.89
- 4.9
- 145.82
- Bharat Immunologica And Bio Corp
- 23.78
- -0.16
- -0.67
- 35.88
- 19
- 102.42
- Ind Swift
- 18.13
- -0.5
- -2.68
- 34.49
- 12
- 98.2
- Makers Laboratories
- 151.15
- 5.5
- 3.78
- 230
- 122
- 89.19
- Zenlabs Ethica
- 33.2
- -0.75
- -2.21
- 52.1
- 27.33
- 21.61
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Welcure Drugs And Pharmaceutic
- 37.89
- 1.5
- 3.72
- 8.15
- Bharat Immunologica And Bio Corp
- -
- 1.18
- -23.67
- -16.7
- Ind Swift
- 12.89
- -
- -
- 12.55
- Makers Laboratories
- 10.56
- 1.22
- 0.37
- 3.25
- Zenlabs Ethica
- 82.8
- 2.12
- 6.1
- 0.94
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 30-May-25
- Audited Results
- 11-Feb-25
- Quarterly Results
- 14-Nov-24
- Quarterly Results
- 13-Aug-24
- Quarterly Results
- 14-May-24
- Audited Results
- 14-Feb-24
- Quarterly Results
- 13-Feb-24
- Quarterly Results
- 09-Nov-23
- Quarterly Results
- 10-Aug-23
- Quarterly Results
- 30-May-23
- Audited Results
- Meeting Date
- Announced on
- Purpose
- 22-Feb-25
- 20-Jan-25
- COM
- 30-Sept-24
- 19-Aug-24
- AGM
- 19-Mar-24
- 15-Feb-24
- POM
- 06-Oct-23
- 03-Oct-23
- EGM
- 30-Sept-23
- 31-Aug-23
- AGM



